Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Pfizer |
---|---|
Information provided by: | Pfizer |
ClinicalTrials.gov Identifier: | NCT00139685 |
To evaluate and compare Bone Mineral Density (BMD) in adolescent Depo-Provera Contraceptive Injection (DP150CI) users during depo medroxyprogesterone acetate (DMPA) therapy and following discontinuation of DMPA. Another group electing non-hormonal contraception or abstinence will be recruited as a reference population, across all study sites. The primary variable is BMD, measured by Dual Energy X-ray Absorptiometry (DXA). Secondary variables are: Total Body Composition& Total Body Calcium (TBC), measured by Dual Energy X-ray Absorptiometry (DXA), and surrogate biologic BMD markers. Safety will be evaluated by adverse event reporting, laboratory evaluations, pregnancies, weight and vital signs.
Condition | Intervention | Phase |
---|---|---|
Contraception Bone Density |
Drug: Depo-Provera Contraceptive Injection - DP150CI |
Phase IV |
Study Type: | Interventional |
Study Design: | Diagnostic, Randomized, Open Label, Active Control, Parallel Assignment, Safety Study |
Official Title: | Depo-Provera: Evaluation of Bone Mineral Density and Total Body Calcium in Adolescent DP 150 CI Users and Matched Controls |
Estimated Enrollment: | 350 |
Study Start Date: | April 1998 |
Study Completion Date: | July 2007 |
Primary Completion Date: | August 2006 (Final data collection date for primary outcome measure) |
Ages Eligible for Study: | 12 Years to 18 Years |
Genders Eligible for Study: | Female |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
United States, California | |
Pfizer Investigational Site | |
Palo Alto, California, United States | |
Pfizer Investigational Site | |
Los Angeles, California, United States | |
Pfizer Investigational Site | |
Torrance, California, United States | |
United States, Kentucky | |
Pfizer Investigational Site | |
Louisville, Kentucky, United States | |
United States, Maryland | |
Pfizer Investigational Site | |
Baltimore, Maryland, United States | |
United States, Michigan | |
Pfizer Investigational Site | |
Detroit, Michigan, United States | |
United States, New York | |
Pfizer Investigational Site | |
Bronx, New York, United States | |
United States, Ohio | |
Pfizer Investigational Site | |
Columbus, Ohio, United States | |
Pfizer Investigational Site | |
Cleveland, Ohio, United States | |
United States, Pennsylvania | |
Pfizer Investigational Site | |
Pittsburgh, Pennsylvania, United States | |
United States, Rhode Island | |
Pfizer Investigational Site | |
Providence, Rhode Island, United States | |
United States, Virginia | |
Pfizer Investigational Site | |
Norfolk, Virginia, United States |
Study Director: | Pfizer CT.gov Call Center | Pfizer |
Responsible Party: | Pfizer, Inc. ( Director, Clinical Trial Disclosure ) |
Study ID Numbers: | Z54000261 |
Study First Received: | August 29, 2005 |
Last Updated: | September 23, 2008 |
ClinicalTrials.gov Identifier: | NCT00139685 |
Health Authority: | United States: Food and Drug Administration |
Calcium, Dietary Medroxyprogesterone 17-Acetate Medroxyprogesterone |
Antineoplastic Agents, Hormonal Antineoplastic Agents Contraceptive Agents Therapeutic Uses Physiological Effects of Drugs Contraceptives, Oral |
Contraceptive Agents, Female Contraceptives, Oral, Synthetic Reproductive Control Agents Contraceptive Agents, Male Pharmacologic Actions |